Clinical Trials Sponsored by Ortho Biotech Clinical Affairs, L.L.C.

Total 64 results

Ortho Biotech, Inc.

Completed

The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)

Anemia
Ortho Biotech, Inc.

Completed

Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy

Cancer | Anemia | Chemotherapy
University of Florida
Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Completed

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Peripheral Neuropathy, Chemotherapy-induced

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Hemostasis, Surgical
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Completed

A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Anemia | Renal Failure , Chronic
University of Texas Southwestern Medical Center
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Centocor Ortho Biotech Services, L.L.C.

Completed

Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands

Hepatosplenic T-cell Lymphoma

Netherlands
Centocor Ortho Biotech Services, L.L.C.

Completed

PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

Psoriasis
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers

Healthy

United States
Centocor Ortho Biotech Services, L.L.C.

Completed

The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Arthritis, Rheumatoid
Centocor Ortho Biotech Services, L.L.C.

Completed

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

Lymphoma

United States
Centocor Ortho Biotech Services, L.L.C.

Completed

APART Advanced Profiling of Anti-Rheumatic Therapies

Arthritis, Rheumatoid
Centocor Ortho Biotech Services, L.L.C.

Completed

Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept

Rheumatoid Arthritis
Mayo Clinic
Centocor Ortho Biotech Services, L.L.C.

Completed

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

Crohn's Disease

United States
University of Arkansas
National Institutes of Health (NIH); Ortho Biotech Clinical Affairs, L.L.C.

Completed

Effects of Exercise in Combination With Epoetin Alfa

Multiple Myeloma

United States
Rheumazentrum Ruhrgebiet
Centocor Ortho Biotech Services, L.L.C.

Unknown

European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study (EASIC registry)

Ankylosing Spondylitis

Belgium, Germany, Finland, France, Netherlands, United Kingdom
Centocor Ortho Biotech Services, L.L.C.
Schering-Plough

Completed

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Crohn Disease

United States, France, United Kingdom, Germany, Spain, Belgium, Israel, Greece, Canada, Netherlands, Austria, Norway, Denmark, Sweden, Portugal
Centocor Ortho Biotech Services, L.L.C.
Schering-Plough

Completed

RESTART C0168Z05 Rheumatoid Arthritis Study

Rheumatoid Arthritis

United States, United Kingdom, Spain, Israel, Finland, Canada, France, Austria, Germany, Netherlands
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Multiple Myeloma

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
University of Rochester
Centocor Ortho Biotech Services, L.L.C.

Completed

Monroe County Inflammatory Bowel Disease (IBD) Registry

Crohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Withdrawn

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Larry Cripe, MD
Celgene Corporation; Ortho Biotech Clinical Affairs, L.L.C.; Walther Cancer Institute

Terminated

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
National Institute of Diabetes and Digestive and...
Schering-Plough; Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation (LADR)

Hepatitis C

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Completed

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Anemia | Venous Thrombosis
Dallas VA Medical Center
Centocor Ortho Biotech Services, L.L.C.

Completed

Exacerbating Factors in Inflammatory Bowel Disease

Crohn's Disease | Ulcerative Colitis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Terminated

A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

Neoplasms
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS); PPD; Ortho Biotech...

Withdrawn

Epoetin Alfa for HIV-Associated Neuropathy Trial

HIV Infections | Neuropathy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Anemia | Surgery, Arthroscopy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Treatment of Anemia in Diabetic Subjects With CKD

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

The Duration Study

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Cancer | Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Rheumatoid Arthritis | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Anemia | Aged | Hemoglobins
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Anemia | Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Anemia

United States

Clinical Trials Sponsored by Ortho Biotech Clinical Affairs, L.L.C.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations